Scholarlink

Background <p>HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment. This study aimed to determine the effectiveness rate of dolutegravir-based treatment among HIV/AIDS patients.</p> Methods <p>A retrospective observational study was conducted among HIV/AIDS patients who started antiretroviral treatment since 48 weeks of follow-up.</p> Results <p>The effectiveness rate of dolutegravir-based treatment was 85.1%. HIV/AIDS patients with a CD4 + count below 200 cel/mm<sup>3</sup>, singles, and HIV/AIDS patients whose treatment duration exceeded 12 months were at risk and likely to have an active infection (<i>P</i> <i>= 0.0001</i>).</p> Conclusion <p>Dolutegravir-based treatment remains effective among HIV/AIDS patients treated at the Nkembo Outpatient Treatment Center.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月3日

查看全文
  • Christian Mangala,
  • Rolf Moukanda-Ifoundou,
  • Denis Maulot-Bangola,
  • Alain Moutsinga,
  • Christian Mombo-Maganga,
  • Serge Christian Okolongo-Mayani,
  • Brice Ongali,
  • Guy Joseph Lemamy,
  • Rachyda Massolou-Outata

摘要

Background

HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment. This study aimed to determine the effectiveness rate of dolutegravir-based treatment among HIV/AIDS patients.

Methods

A retrospective observational study was conducted among HIV/AIDS patients who started antiretroviral treatment since 48 weeks of follow-up.

Results

The effectiveness rate of dolutegravir-based treatment was 85.1%. HIV/AIDS patients with a CD4 + count below 200 cel/mm3, singles, and HIV/AIDS patients whose treatment duration exceeded 12 months were at risk and likely to have an active infection (P = 0.0001).

Conclusion

Dolutegravir-based treatment remains effective among HIV/AIDS patients treated at the Nkembo Outpatient Treatment Center.